Ahmet Ozdemir | Medicinal Chemistry | Best Researcher Award

Dr Ahmet Ozdemir | Medicinal Chemistry | Best Researcher Award

Professor Doctorate, Anadolu University ,Turkey.

Ahmet ÖZDEMİR, born on July 24, 1972, in Muğla, Turkey, is a Professor of Pharmaceutical Chemistry at Anadolu University, where he has been a faculty member since 1997. He earned his undergraduate degree in Pharmacy from Anadolu University (1990-1994), followed by an M.Sc. in Pharmaceutical Chemistry (1995-1996) and a Ph.D. in the same field (1996-2004), with research focusing on the synthesis and biological activities of novel compounds. Dr. ÖZDEMİR has held various academic positions at Anadolu University, advancing from Research Assistant to Professor. He has also served in administrative roles, including Associate Director of Anadolu University Yunus Emre Vocational School and Vice Academic Director of the Open Education Faculty’s Department of Health Administration. His research is well-regarded, earning him multiple awards, including the Anadolu University Article Performance Award and the ISIF’21 Silver Medal for his work on targeted novel triazolothiadiazine derivatives for lung cancer treatment.

Profile:

Education

Prof. Dr. Ahmet Özdemir’s educational journey began at Salihli Cumhuriyet Elementary School, where he completed his primary education from 1978 to 1983. He continued his secondary education at Salihli 50. Yıl Secondary School from 1983 to 1986, and then attended Salihli High School from 1986 to 1989, where he completed his high school education. Prof. Dr. Özdemir pursued his undergraduate studies at Anadolu University Faculty of Pharmacy, graduating in 1994. He furthered his education with a Master’s Degree in Pharmaceutical Chemistry at Anadolu University’s Graduate School of Health Sciences from 1995 to 1996, where he completed his thesis. He continued at Anadolu University for his Doctoral Degree in Pharmaceutical Chemistry, which he achieved in 2004. Additionally, he possesses intermediate proficiency in English, which complements his academic background and research expertise.

Academic Titles

Prof. Dr. Ahmet Özdemir’s academic career at Anadolu University’s Faculty of Pharmacy spans several roles and achievements. He began his journey as a Research Assistant in 1997, a position he held until 2004. Following this, he advanced to the role of Research Assistant Doctor, continuing his work at the same institution from 2004 to 2005. Dr. Özdemir was then appointed as a Lecturer from 2005 to 2007, showcasing his growing expertise in the field. His contributions were recognized with a promotion to Assistant Professor Doctor, a role he embraced from 2007 to 2010. His exceptional work led to his promotion to Associate Professor Doctor, a position he held from 2010 to 2015. Since 2015, Prof. Dr. Özdemir has served as Professor Doctor, continuing to make significant contributions to the Faculty of Pharmacy and the broader academic community.

Awards

Prof. Dr. Ahmet Özdemir has received several prestigious awards for his academic and research contributions. In 2014, he was honored with the Anadolu University Article Performance Award. His outstanding achievements continued with the Anadolu University Gold Article Performance Award and the Anadolu University Platinum Article Performance Award in 2015. He maintained a high standard of excellence, receiving the Anadolu University Article Performance Award annually from 2016 to 2018. In 2019, Dr. Özdemir was recognized with the Anadolu University Academic Success Award. His consistent performance earned him the Anadolu University Article Performance Award again in 2020. Notably, in 2021, he was awarded the ISIF’21 Silver Medal for the invention titled “Targeted Novel Triazolothiadiazine Derivatives for the Treatment of Lung Cancer” at the 6th Istanbul International Inventions Fair (ISIF’21). This award was shared with Assoc. Prof. Dr. Belgin Sever, Prof. Dr. Mehlika Dilek Altintop, and Prof. Dr. Gülşen Akalın Çiftçi.

Research Focus

Prof. Dr. Ahmet Özdemir’s research is dedicated to the field of medicinal chemistry, with a keen focus on several key areas. He specializes in the synthesis of bioactive compounds, aiming to develop novel chemical entities with potential therapeutic uses, particularly targeting antifungal and antibacterial applications. His work in pharmaceutical chemistry involves investigating the physicochemical properties of these compounds, which has significant implications for drug design and efficacy. Dr. Özdemir also explores antimicrobial agents, focusing on the synthesis and evaluation of compounds designed to combat bacterial and fungal pathogens. In the realm of drug design and development, he examines structure-activity relationships to create effective and selective pharmaceutical agents. Additionally, his contributions extend to invention and innovation, where he develops novel chemical derivatives, such as triazolothiadiazine derivatives, for potential applications in treating diseases like lung cancer.

Publications

  1. “Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy”
    • Authors: Altıntop, M.D., Ertorun, İ., Akalın Çiftçi, G., Özdemir, A.
    • Year: 2024
  2. “Design, Synthesis, and In Vivo Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents”
    • Authors: Baramaki, I., Altıntop, M.D., Arslan, R., Hasan, A., Bektaş Türkmen, N.
    • Year: 2024
  3. “Design, Synthesis, and Evaluation of a New Series of 2-Pyrazolines as Potential Antileukemic Agents”
    • Authors: Altıntop, M.D., Cantürk, Z., Özdemir, A.
    • Year: 2023
  4. “Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy”
    • Authors: Erdönmez, B., Altıntop, M.D., Akalın Çiftçi, G., Özdemir, A., Ece, A.
    • Year: 2023
  5. “A new series of hydrazones as small-molecule aldose reductase inhibitors”
    • Authors: Altıntop, M.D., Demir, Y., Türkeş, C., Beydemir, Ş., Özdemir, A.
    • Year: 2023
  6. “A new series of thiazole-hydrazone hybrids for Akt-targeted therapy of non-small cell lung cancer”
    • Authors: Orujova, T., Ece, A., Akalın Çiftçi, G., Özdemir, A., Altıntop, M.D.
    • Year: 2023
  7. “Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action”
    • Authors: Altıntop, M.D., Akalın Çiftçi, G., Yılmaz Savaş, N., Alataş, Ö., Özdemir, A.
    • Year: 2023
  8. “Microwave-assisted synthesis of a series of 4,5-dihydro-1H-pyrazoles endowed with selective COX-1 inhibitory potency”
    • Authors: Altıntop, M.D., Temel, H.E., Özdemir, A.
    • Year: 2023
  9. “Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer”
    • Authors: Altıntop, M.D., Özdemir, A., Temel, H.E., Kaplancıklı, Z.A., Akalın Çiftçi, G.
    • Year: 2022
  10. “A new series of thiosemicarbazone-based anti-inflammatory agents exerting their action through cyclooxygenase inhibition”
    • Authors: Altıntop, M.D., Sever, B., Akalın Çiftçi, G., Alataş, Ö., Özdemir, A.
    • Year: 2022

 

Taigang Liang | Drug Design | Best Researcher Award

Prof. Taigang Liang | Drug Design | Best Researcher Award

Professor at School of Pharmacy/Shanxi Medical University, China.

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Professional Profiles:

Education

Prof. Tai Gang Liang, a distinguished scientist at Shanxi Medical University’s School of Pharmacy, has a robust educational background in pharmaceutical sciences. He earned his Doctor of Philosophy (PhD) in 2011, Master of Science (MS) in 2003, and Bachelor of Science (BS) in 2000, all from Shanxi Medical University. His extensive expertise spans drug synthesis, drug action mechanisms, computer-aided drug design, and the industrialization of traditional Chinese medicine (TCM). Prof. Liang’s research is recognized for its contributions to both the development of novel drug compounds and innovative drug design methodologies. His academic journey reflects a deep commitment to advancing pharmaceutical sciences and addressing global health challenges through cutting-edge research.

Professional Experience

Prof. Tai Gang Liang is a distinguished scientist at the School of Pharmacy, Shanxi Medical University, with extensive expertise in drug synthesis, drug action mechanisms, and computer-aided drug design. His research also focuses on the industrialization of traditional Chinese medicine (TCM). Over his career, Prof. Liang has received several prestigious awards, including being named a Shanxi Province Outstanding Young Scholar and a member of the Shanxi Province “131 Leading Talent Engineering.” He also earned the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition. His work has made significant contributions to advancing pharmaceutical sciences and TCM research, reflecting his dedication to innovation and excellence in the field.

 Research Interest

Prof. Tai Gang Liang’s research interests encompass a broad spectrum within pharmaceutical sciences. His primary focus includes drug synthesis and drug action mechanisms, where he aims to develop novel therapeutic agents and understand their biological effects. He is also deeply involved in computer-aided drug design, utilizing computational tools to optimize drug development processes. Additionally, Prof. Liang investigates the industrialization of traditional Chinese medicine (TCM), striving to integrate traditional practices with modern scientific techniques to enhance the efficacy and application of TCM therapies. His research aims to bridge the gap between traditional and modern medicinal approaches, advancing both fields through innovative solutions and interdisciplinary collaboration.

Award and Honors

Prof. Tai Gang Liang has received several notable awards and honors in recognition of his contributions to the field of pharmaceutical sciences. He was named a Shanxi Province Outstanding Young Scholar, highlighting his exceptional achievements and potential in his research domain. He is also a member of the Shanxi Province “131 Leading Talent Engineering”, an accolade given to influential professionals in the province. Additionally, Prof. Liang was awarded the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition, reflecting his innovative approach and entrepreneurial spirit in scientific endeavors. These accolades underscore his dedication and significant impact in drug development and traditional Chinese medicine. 🏆🌟

 Research Skills

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Publications
  1. Green synthesis of selenium nanoparticles with extract of hawthorn fruit induced HepG2 cells apoptosis
    • Authors: D Cui, T Liang, L Sun, L Meng, C Yang, L Wang, T Liang, Q Li
    • Year: 2018
    • Citations: 112
  2. Comparison of the Phenolic Content and Antioxidant Activities of Apocynum venetum L. (Luo-Bu-Ma) and Two of Its Alternative Species
    • Authors: T Liang, W Yue, Q Li
    • Year: 2010
    • Citations: 107
  3. Selenium nanoparticles fabricated in laminarin polysaccharides solutions exert their cytotoxicities in HepG2 cells by inhibiting autophagy and promoting apoptosis
    • Authors: D Cui, J Ma, T Liang, L Sun, L Meng, T Liang, Q Li
    • Year: 2019
    • Citations: 93
  4. Synthesis, characterization and antitumor properties of selenium nanoparticles coupling with ferulic acid
    • Authors: D Cui, C Yan, J Miao, X Zhang, J Chen, L Sun, L Meng, T Liang, Q Li
    • Year: 2018
    • Citations: 78
  5. Chemopreventive Effects of Peucedanum praeruptorum DUNN and Its Major Constituents on SGC7901 Gastric Cancer Cells
    • Authors: T Liang, W Yue, Q Li
    • Year: 2010
    • Citations: 51
  6. Farrerol Directly Targets GSK‐3β to Activate Nrf2‐ARE Pathway and Protect EA.hy926 Cells against Oxidative Stress‐Induced Injuries
    • Authors: C Yan, X Zhang, J Miao, H Yuan, E Liu, T Liang, Q Li
    • Year: 2020
    • Citations: 37
  7. Apoptosis induced by farrerol in human gastric cancer SGC-7901 cells through the mitochondrial-mediated pathway
    • Authors: E Liu, T Liang, X Wang, S Ban, L Han, Q Li
    • Year: 2015
    • Citations: 35
  8. Diorganotin (IV) complexes with 4-nitro-N-phthaloyl-glycine: Synthesis, characterization, antitumor activity and DNA-binding studies
    • Authors: C Yan, J Zhang, T Liang, Q Li
    • Year: 2015
    • Citations: 35
  9. Relaxation of rat aorta by farrerol correlates with potency to reduce intracellular calcium of VSMCs
    • Authors: X Qin, X Hou, M Zhang, T Liang, J Zhi, L Han, Q Li
    • Year: 2014
    • Citations: 31
  10. Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest
    • Authors: E Liu, J Li, S Shi, X Wang, T Liang, B Wu, Q Li
    • Year: 2016
    • Citations: 26